• V Aliamus, C Adam, M Druet-Cabanac, T Dantoine, and A Vergnenegre.
• Registre général des cancers du Limousin, SIME, hôpital du Cluzeau, CHU Dupuytren, 23, avenue Dominique-Larrey, 87042 Limoges cedex, France.
• Rev Mal Respir. 2011 Nov 1;28(9):1124-30.

BackgroundLung cancer is a frequently occurring disease among elderly people. The objective of this study was to search for a relationship between multimodal geriatric assessment and a decision-making in the treatment of patients with this condition.MethodsForty-nine elderly patients (aged 70 years and over) diagnosed with a primary lung cancer underwent a geriatric assessment before decision for treatment was made in a multidisciplinary meeting. We described the impact of the geriatric assessment on the management decisions made.ResultsAlmost half of treatment (44.9%) decisions were modified by the geriatric assessment. For patients with so called "pre-frailty" according to Balducci's criteria, 60% of treatment decisions were modified by the results of geriatric assessment (use of only one chemotherapeutic drug, dose disease or best supportive care). For this group of patients, Folstein MMSE and IADL were predictive of change in decision-making, with the threshold estimated to be 26 points. Only the MMSE was significantly associated with the medical decision in multivariate analysis.ConclusionGeriatric assessment should be integrated into treatment decision-making for patients with primary lung cancer aged more than 70 years, particularly those where frailty is a concern. Folstein's MMSE was predictive in our study for changes in decision-making.Copyright © 2011 SPLF. Published by Elsevier Masson SAS. All rights reserved.

25 keywords...

hide…